

# Christine Marosi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7483215/publications.pdf>

Version: 2024-02-01

190  
papers

35,943  
citations

36303

51  
h-index

3830

178  
g-index

225  
all docs

225  
docs citations

225  
times ranked

31863  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. <i>New England Journal of Medicine</i> , 2005, 352, 987-996.	27.0	17,395
2	Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. <i>Lancet Oncology</i> , The, 2009, 10, 459-466.	10.7	6,451
3	Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 916-926.	10.7	1,075
4	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. <i>Lancet Oncology</i> , The, 2017, 18, e315-e329.	10.7	816
5	Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	10.7	776
6	Prediction of venous thromboembolism in cancer patients. <i>Blood</i> , 2010, 116, 5377-5382.	1.4	643
7	Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1064-1075.	1.2	485
8	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	10.7	458
9	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2016, 17, 1521-1532.	10.7	396
10	Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). <i>Neuro-Oncology</i> , 2017, 19, 162-174.	1.2	381
11	Meningioma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 153-171.	4.4	301
12	MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. <i>Acta Neuropathologica</i> , 2012, 124, 547-560.	7.7	274
13	MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2057-2064.	7.0	264
14	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. <i>Nature Medicine</i> , 2018, 24, 1611-1624.	30.7	229
15	Correlation of immune phenotype with IDH mutation in diffuse glioma. <i>Neuro-Oncology</i> , 2017, 19, 1460-1468.	1.2	213
16	European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. <i>Lancet Oncology</i> , The, 2017, 18, e330-e340.	10.7	195
17	Anti-Methylguanine-Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*. <i>Brain Pathology</i> , 2008, 18, 520-532.	4.1	189
18	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016, 18, 549-556.	1.2	187

#	ARTICLE	IF	CITATIONS
19	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. <i>Heart</i> , 2015, 101, 1874-1880.	2.9	181
20	P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. <i>Journal of Neuro-Oncology</i> , 2005, 72, 255-260.	2.9	176
21	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. <i>Blood</i> , 2017, 129, 1831-1839.	1.4	164
22	Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222.	7.7	163
23	A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013, 4, 502-530.	1.8	152
24	5-Aminolevulinic Acid Induced Fluorescence Is a Powerful Intraoperative Marker for Precise Histopathological Grading of Gliomas with Non-Significant Contrast-Enhancement. <i>PLoS ONE</i> , 2013, 8, e76988.	2.5	138
25	Vascular Patterns in Glioblastoma Influence Clinical Outcome and Associate with Variable Expression of Angiogenic Proteins: Evidence for Distinct Angiogenic Subtypes. <i>Brain Pathology</i> , 2003, 13, 133-143.	4.1	132
26	Venous thromboembolism and survival in patients with high-grade glioma. <i>Neuro-Oncology</i> , 2007, 9, 89-95.	1.2	119
27	Clinical fMRI: Evidence for a 7T benefit over 3T. <i>NeuroImage</i> , 2011, 57, 1015-1021.	4.2	110
28	Challenge of cancer in the elderly. <i>ESMO Open</i> , 2016, 1, e000020.	4.5	107
29	Phase II Study of Radiotherapy and Temozolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082). <i>Clinical Cancer Research</i> , 2016, 22, 4797-4806.	7.0	105
30	Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2014, 111, 670-678.	3.4	88
31	Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies. <i>Neurosurgical Review</i> , 2012, 35, 381-391.	2.4	86
32	Chromosome 7 gain and DNA hypermethylation at the <i>HOXA10</i> locus are associated with expression of a stem cell related <i>HOX</i> -signature in glioblastoma. <i>Genome Biology</i> , 2015, 16, 16.	8.8	82
33	Citrullinated histone H3, a biomarker for neutrophil extracellular trap formation, predicts the risk of mortality in patients with cancer. <i>British Journal of Haematology</i> , 2019, 186, 311-320.	2.5	82
34	Neurocognitive training in patients with high-grade glioma: a pilot study. <i>Journal of Neuro-Oncology</i> , 2010, 97, 109-115.	2.9	78
35	Influence of adjunctive classical homeopathy on global health status and subjective wellbeing in cancer patients – A pragmatic randomized controlled trial. <i>Complementary Therapies in Medicine</i> , 2015, 23, 309-317.	2.7	78
36	The DNA methylome of <i>DDR</i> genes and benefit from RT or TMZ in <i>IDH</i> mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018, 135, 601-615.	7.7	76

#	ARTICLE	IF	CITATIONS
37	A novel tool to analyze MRI recurrence patterns in glioblastoma. <i>Neuro-Oncology</i> , 2008, 10, 1019-1024.	1.2	74
38	The caregiversâ€™ perspective on the end-of-life phase of glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2013, 112, 403-411.	2.9	72
39	Expression of Telomeres in Astrocytoma WHO Grade 2 to 4: TERRA Level Correlates with Telomere Length, Telomerase Activity, and Advanced Clinical Grade. <i>Translational Oncology</i> , 2012, 5, 56-IN4.	3.7	71
40	Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. <i>Cancer Genetics and Cytogenetics</i> , 1992, 61, 14-25.	1.0	70
41	The end-of-life phase of high-grade glioma patients: a systematic review. <i>Supportive Care in Cancer</i> , 2014, 22, 847-857.	2.2	68
42	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. <i>Cancers</i> , 2018, 10, 372.	3.7	67
43	Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 357-368.	3.3	66
44	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>PLoS ONE</i> , 2014, 9, e111440.	2.5	64
45	Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 1645-1651.	1.2	63
46	Plasma MicroRNA-21 Concentration May Be a Useful Biomarker in Glioblastoma Patients. <i>Cancer Investigation</i> , 2012, 30, 615-621.	1.3	60
47	Trabectedin has promising antineoplastic activity in high-grade meningioma. <i>Cancer</i> , 2012, 118, 5038-5049.	4.1	57
48	A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). <i>Neuro-Oncology</i> , 2014, 16, 92-102.	1.2	57
49	Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. <i>FASEB Journal</i> , 2005, 19, 960-962.	0.5	56
50	Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. <i>Journal of Neuro-Oncology</i> , 2003, 63, 55-61.	2.9	53
51	Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. <i>Thrombosis Research</i> , 2013, 131, 162-165.	1.7	53
52	Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. <i>Neuro-Oncology</i> , 2016, 18, 401-407.	1.2	53
53	Seven Novel and Stable Translocations Associated with Oncogenic Gene Expression in Malignant Melanoma. <i>Neoplasia</i> , 2005, 7, 303-311.	5.3	52
54	Exploratory investigation of eight circulating plasma markers in brain tumor patients. <i>Neurosurgical Review</i> , 2013, 36, 45-56.	2.4	48

#	ARTICLE	IF	CITATIONS
55	[11C] Methionine and [18F] Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007, 84, 305-314.	2.9	44
56	Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. <i>Journal of Neuro-Oncology</i> , 2012, 109, 331-339.	2.9	43
57	Survival and prognostic factors of patients with unresectable glioblastoma multiforme. <i>Anti-Cancer Drugs</i> , 2003, 14, 305-312.	1.4	42
58	Association of platelet activation markers with cancer-associated venous thromboembolism. <i>Platelets</i> , 2016, 27, 80-85.	2.3	42
59	Recurrent and metastatic clivus chordoma: systemic palliative therapy retards disease progression. <i>Anti-Cancer Drugs</i> , 2005, 16, 1139-1143.	1.4	41
60	Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T. <i>Magnetic Resonance Imaging</i> , 2012, 30, 139-147.	1.8	39
61	Prevalence of clinically relevant oral mucositis in outpatients receiving myelosuppressive chemotherapy for solid tumors. <i>Supportive Care in Cancer</i> , 2012, 20, 175-183.	2.2	39
62	Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. <i>Acta Oncologica</i> , 2011, 50, 630-635.	1.8	38
63	Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1875-1884.	3.4	38
64	Preoperative Diffusion-Weighted Imaging of Single Brain Metastases Correlates with Patient Survival Times. <i>PLoS ONE</i> , 2013, 8, e55464.	2.5	38
65	Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencil) trial: immune system characteristics influence outcome and Audencil up-regulates Th1-related immunovariabiles. <i>Acta Neuropathologica Communications</i> , 2018, 6, 135.	5.2	37
66	Neuromuscular electrical stimulation for a patient with metastatic lung cancer—a case report. <i>Supportive Care in Cancer</i> , 2006, 14, 970-973.	2.2	36
67	Temozolomide Dosing Regimens for Glioma Patients. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 286-293.	4.2	34
68	Tetrasomy 8 in acute monoblastic leukemia (AML-M5a) with myelosarcomatosis of the skin. <i>Cancer Genetics and Cytogenetics</i> , 1993, 71, 50-54.	1.0	31
69	Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO). <i>Neuro-Oncology</i> , 2013, 15, 112-121.	1.2	31
70	Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. <i>Anti-Cancer Drugs</i> , 2003, 14, 437-442.	1.4	30
71	Epithelial Growth Factor Receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. <i>Journal of Neuro-Oncology</i> , 2008, 89, 211-218.	2.9	27
72	Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. <i>Journal of Neuro-Oncology</i> , 2010, 97, 305-308.	2.9	27

#	ARTICLE	IF	CITATIONS
73	Gamma Knife Radiosurgery in Recurrent Glioblastoma. <i>Stereotactic and Functional Neurosurgery</i> , 2016, 94, 265-272.	1.5	27
74	Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases. <i>Cancer</i> , 2020, 126, 4341-4352.	4.1	27
75	Prognostic impact of genetic alterations and methylation classes in meningioma. <i>Brain Pathology</i> , 2022, 32, e12970.	4.1	27
76	Interferon-alfa-2b for meningioma. <i>Lancet, The</i> , 1995, 345, 331.	13.7	26
77	No prognostic impact of survivin expression in glioblastoma. <i>Acta Neuropathologica</i> , 2005, 109, 534-538.	7.7	26
78	Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. <i>European Radiology</i> , 2017, 27, 1556-1567.	4.5	26
79	The course of quality of life and neurocognition in newly diagnosed patients with glioblastoma. <i>Radiotherapy and Oncology</i> , 2017, 125, 228-233.	0.6	26
80	The prognostic value of [123I]-vascular endothelial growth factor ([123I]-VEGF) in glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2396-2403.	6.4	25
81	Association of complete blood count parameters, d-dimer, and soluble P-selectin with risk of arterial thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1335-1344.	3.8	25
82	Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 187-198.	2.9	25
83	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	1.2	25
84	Malignant spinal cord compression in cerebral glioblastoma multiforme: a multicenter case series and review of the literature. <i>Journal of Neuro-Oncology</i> , 2012, 110, 221-226.	2.9	24
85	Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study. <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 481-486.	1.9	24
86	Additive homeopathy in cancer patients: Retrospective survival data from a homeopathic outpatient unit at the Medical University of Vienna. <i>Complementary Therapies in Medicine</i> , 2014, 22, 320-332.	2.7	24
87	Assessing <i>MGMT</i> methylation status and its current impact on treatment in glioblastoma. <i>CNS Oncology</i> , 2015, 4, 47-52.	3.0	24
88	MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. <i>Pituitary</i> , 2017, 20, 643-653.	2.9	24
89	Molecular biology of high-grade gliomas: what should the clinician know?. <i>Chinese Journal of Cancer</i> , 2014, 33, 4-7.	4.9	24
90	Cancer rehabilitation: current trends and practices within an Austrian University Hospital Center. <i>Disability and Rehabilitation</i> , 2020, 42, 2-7.	1.8	23

#	ARTICLE	IF	CITATIONS
91	Prognostic relevance of p53 protein expression in glioblastoma. <i>Oncology Reports</i> , 2002, 9, 703-7.	2.6	23
92	Stabilization of a Progressive Hemangioblastoma under Treatment with Thalidomide. <i>Journal of Neuro-Oncology</i> , 2004, 66, 295-299.	2.9	22
93	Diversity of cytogenetic and pathohistologic profiles in glioblastoma. <i>Cancer Genetics and Cytogenetics</i> , 2006, 166, 46-55.	1.0	22
94	Response to imatinib as a function of target kinase expression in recurrent glioblastoma. <i>SpringerPlus</i> , 2014, 3, 111.	1.2	21
95	Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2012, 109, 323-330.	2.9	20
96	Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. <i>Journal of Neurology</i> , 2015, 262, 179-186.	3.6	20
97	Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study. <i>Oncologist</i> , 2020, 25, e1930-e1955.	3.7	20
98	Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 294-298.	2.3	19
99	Blood Alterations Preceding Clinical Manifestation of Glioblastoma. <i>Cancer Investigation</i> , 2012, 30, 625-629.	1.3	19
100	Cancer rehabilitation in Austriaâ€™s aspects of Physical Medicine and Rehabilitation. <i>Wiener Medizinische Wochenschrift</i> , 2016, 166, 39-43.	1.1	19
101	Distributed changes of the functional connectome in patients with glioblastoma. <i>Scientific Reports</i> , 2020, 10, 18312.	3.3	19
102	Determining medical decision-making capacity in brain tumor patients: why and how?. <i>Neuro-Oncology Practice</i> , 2020, 7, 599-612.	1.6	19
103	Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors. <i>Npj Vaccines</i> , 2020, 5, 5.	6.0	19
104	Glioblastoma with Spinal Seeding. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 455-457.	2.0	18
105	Strength of skeletal muscle and self-reported physical performance in Austrian glioblastoma-patients. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 377-383.	1.9	18
106	Does 99mTc-Sestamibi in High-Grade Malignant Brain Tumors Reflect Bloodâ€™Brain Barrier Damage Only?. <i>NeuroImage</i> , 2000, 12, 109-111.	4.2	17
107	Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours. <i>ESMO Open</i> , 2020, 5, e000863.	4.5	17
108	Translocation (16;21)(p11;q22) in acute monoblastic leukemia with erythrophagocytosis. <i>Cancer Genetics and Cytogenetics</i> , 1991, 54, 61-66.	1.0	16

#	ARTICLE	IF	CITATIONS
109	Karyotypic Findings in Two Cases of Male Breast Cancer. <i>Cancer Genetics and Cytogenetics</i> , 2000, 121, 190-193.	1.0	16
110	Unexpected out-of-hospital deaths in persons aged 85 years or older: an autopsy study of 1886 patients. <i>American Journal of Medicine</i> , 2003, 114, 365-369.	1.5	16
111	Neuropathies associated with lymphoma. <i>Neuro-Oncology Practice</i> , 2015, 2, 167-178.	1.6	16
112	Cytogenetic and comparative genomic hybridization findings in four cases of breast cancer after neoadjuvant chemotherapy. <i>Cancer Genetics and Cytogenetics</i> , 2003, 146, 161-166.	1.0	15
113	Frequent overexpression of ErbB " receptor family members in brain metastases of non-small cell lung cancer patients. <i>Apmis</i> , 2013, 121, 1144-1152.	2.0	15
114	Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients. <i>Oncotarget</i> , 2017, 8, 81250-81260.	1.8	15
115	Vascular endothelial growth factor targeted therapy may improve the effect of dendritic cell-based cancer immune therapy. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 76-77.	0.6	15
116	Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies. <i>Anticancer Research</i> , 2013, 33, 1065-71.	1.1	15
117	Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma. <i>Journal of Neuro-Oncology</i> , 2000, 49, 263-268.	2.9	14
118	Myxopapillary Ependymoma With Pleuropulmonary Metastases and High Plasma Glial Fibrillary Acidic Protein Levels. <i>Journal of Clinical Oncology</i> , 2011, 29, e756-e757.	1.6	14
119	Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens. <i>Journal of Neuro-Oncology</i> , 2013, 112, 347-354.	2.9	14
120	Survival improvement in patients with glioblastoma multiforme during the last 20 years in a single tertiary-care center. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 389-397.	1.9	13
121	Feasibility and toxicity of CCNU therapy in elderly patients with glioblastoma multiforme. <i>Anti-Cancer Drugs</i> , 2003, 14, 137-143.	1.4	13
122	Glioblastoma treatment using perphenazine to block the subventricular zone's tumor trophic functions. <i>Journal of Neuro-Oncology</i> , 2014, 116, 207-212.	2.9	13
123	Advances in brain tumour classification and therapy. <i>Nature Reviews Neurology</i> , 2017, 13, 71-72.	10.1	13
124	Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma. <i>Cancers</i> , 2019, 11, 2020.	3.7	13
125	Frequent MGMT (O6-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. <i>Radiology and Oncology</i> , 2010, 44, 113-20.	1.7	11
126	Are hypothyroidism and hypogonadism clinically relevant in patients with malignant gliomas? A longitudinal trial in patients with glioma. <i>Radiotherapy and Oncology</i> , 2019, 130, 139-148.	0.6	11



#	ARTICLE	IF	CITATIONS
127	Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients. <i>Anti-Cancer Drugs</i> , 2001, 12, 209-212.	1.4	10
128	Gender aspects of treatment and drug related toxicity in medical oncology. <i>Wiener Medizinische Wochenschrift</i> , 2006, 156, 534-540.	1.1	10
129	Pilot study on sex hormone levels and fertility in women with malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 107, 387-394.	2.9	10
130	Sorafenib for patients with pretreated recurrent or progressive high-grade glioma. <i>Anti-Cancer Drugs</i> , 2014, 25, 723-728.	1.4	10
131	GDF15 in solid vs non-solid treatment-naïve malignancies. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13168.	3.4	10
132	Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. <i>European Journal of Cancer</i> , 2020, 135, 150-158.	2.8	10
133	Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3643-3650.	4.2	10
134	Case Report: Pregnancy in a patient with recurrent glioblastoma. <i>F1000Research</i> , 2013, 2, 246.	1.6	10
135	Complications of chemotherapy in neuro-oncology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 105, 873-885.	1.8	9
136	High plasma-GFAP levels in metastatic myxopapillary ependymoma. <i>Journal of Neuro-Oncology</i> , 2013, 113, 359-363.	2.9	8
137	Milestones of the last 10 years. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 18-21.	0.5	8
138	Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study. <i>Acta Oncologica</i> , 2019, 58, 967-976.	1.8	8
139	Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI. <i>ESMO Open</i> , 2019, 4, e000538.	4.5	7
140	Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death. <i>Translational Research</i> , 2020, 215, 41-56.	5.0	7
141	The cancer survival index – A prognostic score integrating psychosocial and biological factors in patients diagnosed with cancer or haematologic malignancies. <i>Cancer Medicine</i> , 2022, 11, 3387-3396.	2.8	7
142	MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen. <i>Cancers</i> , 2022, 14, 2563.	3.7	7
143	Microvessel density is not crucial for scintigraphic visualization of brain tumors using 99mTc-MIBI. <i>Microvascular Research</i> , 2004, 67, 218-222.	2.5	6
144	Temozolomide for recurrent or progressive high-grade malignant glioma: Results of an Austrian multicenter observational study. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 230-238.	1.9	6

#	ARTICLE	IF	CITATIONS
145	Chemotherapy for malignant gliomas. Wiener Medizinische Wochenschrift, 2006, 156, 346-350.	1.1	6
146	Guiding Treatment Choices for Elderly Patients with Glioblastoma by a Comprehensive Geriatric Assessment. Current Oncology Reports, 2020, 22, 93.	4.0	6
147	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome including in elderly patients. Acta Neuropathologica Communications, 2022, 10, 39.	5.2	6
148	MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy. Cancers, 2022, 14, 1579.	3.7	6
149	Antiangiogenic Treatment of Meningiomas. Current Treatment Options in Neurology, 2015, 17, 359.	1.8	5
150	Evidence-based management of adult patients with diffuse glioma – Authors' reply. Lancet Oncology, The, 2017, 18, e430-e431.	10.7	5
151	Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience. Anti-Cancer Drugs, 2005, 16, 185-190.	1.4	4
152	The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. ESMO Open, 2017, 2, e000166.	4.5	4
153	Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma. ESMO Open, 2020, 5, e000647.	4.5	4
154	PD1 and PD-L1 expression in glioblastoma.. Journal of Clinical Oncology, 2014, 32, 2011-2011.	1.6	4
155	Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open, 2020, 5, e000880.	4.5	4
156	Preliminary study on pharmacokinetics of dacarbazine and fotemustine in glioblastoma multiforme patients does not indicate gender-specific differences. Anti-Cancer Drugs, 2004, 15, 495-8.	1.4	4
157	Double modulation of 5-fluorouracil by high-dose leucovorin and interferon-2b in advanced colorectal cancer. Journal of Cancer Research and Clinical Oncology, 1994, 120, 314-318.	2.5	3
158	Impaired hemorheology in patients with postmastectomy lymphedema. Breast Cancer Research and Treatment, 1996, 38, 283-288.	2.5	3
159	Cytogenetic Analysis and Fluorescence In Situ Hybridization in a Case of IgD Multiple Myeloma. Cancer Genetics and Cytogenetics, 1998, 105, 172-176.	1.0	3
160	Editorial: Behandlung von Glioblastomrezidiven. Wiener Medizinische Wochenschrift, 2011, 161, 1-2.	1.1	3
161	Evaluation of diagnostic and treatment approaches towards acute dyspnea in a palliative care setting among medical students at the University of Vienna. Wiener Medizinische Wochenschrift, 2012, 162, 18-28.	1.1	3
162	Light at the end of the tunnel: towards an effective drug therapy for surgery- and radiation-refractory meningioma. Neuro-Oncology, 2015, 17, 7-8.	1.2	3

#	ARTICLE	IF	CITATIONS
163	Absence of CMV viremia in high-grade glioma patients under low dosage glucocorticoid treatment. <i>Neuro-Oncology</i> , 2017, 19, 1280-1282.	1.2	3
164	Red Cell Distribution Width and Other Red Blood Cell Parameters in Patients with Cancer: Association with Risk of Venous Thromboembolism and Mortality. <i>Blood</i> , 2014, 124, 2859-2859.	1.4	3
165	Recurrent cardiac tamponade as first manifestation of gastric cancer. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 621-622.	1.6	2
166	Immature and absolute platelet count changes and thrombocytopenia in malignant glioma. <i>European Journal of Clinical Investigation</i> , 2011, 41, 539-545.	3.4	2
167	The Association of Early Cognition Assessments and Progression-free Survival in Patients with Glioblastoma Multiforme. <i>The Journal of Oncopathology</i> , 2014, 1, 1-9.	0.1	2
168	Brain tumors – other treatment modalities. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 547-560.	1.8	2
169	How should adult patients with neurofibromatosis 1 be managed?. <i>Neuro-Oncology</i> , 2018, 20, 721-722.	1.2	2
170	Reply to letter to the editor by Maddocks M. T. et al., “Neuromuscular electrical stimulation (NMES), a proactive supportive therapy or both?” regarding our publication “Neuromuscular electrical stimulation for a patient with metastatic lung cancer” a case report and recent experiences in glioblastoma patients. <i>Supportive Care in Cancer</i> , 2007, 15, 113-113.	2.2	1
171	First-line bevacizumab for glioblastoma: what do recent Trail results mean for future treatment?. <i>CNS Oncology</i> , 2013, 2, 473-474.	3.0	1
172	Geriatric oncology: questions, answers and guidelines. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 24-28.	0.5	1
173	Will mastering ferroptosis allow treating refractory meningiomas?. <i>Neuro-Oncology</i> , 2021, 23, 1989-1990.	1.2	1
174	A randomized clinical trial for the treatment of glioblastoma multiforme with the individualized dendritic cell-based cancer immunotherapy AV0113.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2052-2052.	1.6	1
175	Drug therapy for recurrent, progressive, atypical, and malignant meningiomas. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 218-222.	0.5	0
176	News from the Neuro-Oncology front. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 169-170.	0.5	0
177	The End-of-Life in patients with glioma and their families. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 233-235.	0.5	0
178	Conference Scene: Neuro-oncology insights from European Society of Medical Oncology 2012. <i>CNS Oncology</i> , 2013, 2, 29-31.	3.0	0
179	NTCT-09IGF-1 IS NOT ELEVATED IN PATIENTS WITH HGG TREATED WITH RADIOCHEMOTHERAPY. <i>Neuro-Oncology</i> , 2015, 17, v174.1-v174.	1.2	0
180	Is dosing in oncology gender-sensitive?. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 5-10.	0.5	0

#	ARTICLE	IF	CITATIONS
181	Methylation of PD-1 Promoter Gene as New Prognostic Marker for IDH Mutant Low-Grade Glioma?. EBioMedicine, 2018, 29, 9-10.	6.1	0
182	MNGI-28. CORRELATION OF METHYLATION CLASS AND GENETIC ALTERATIONS WITH PROGRESSION FREE SURVIVAL IN MENINGIOMA. Neuro-Oncology, 2018, 20, vi155-vi155.	1.2	0
183	Elderly patients with cancer. Memo - Magazine of European Medical Oncology, 2021, 14, 1-2.	0.5	0
184	High Soluble P-Selectin and Low Platelet Count as Thrombosis Risk Markers in Glioma Patients.. Blood, 2009, 114, 2985-2985.	1.4	0
185	Correlation of large brain edema with favorable prognosis in patients with single brain metastases.. Journal of Clinical Oncology, 2012, 30, 2053-2053.	1.6	0
186	Factor V Leiden Mutation Increases the Risk of Venous Thromboembolism in Cancer Patients – Results From the Vienna Cancer and Thrombosis Study (CATS).. Blood, 2012, 120, 2253-2253.	1.4	0
187	Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).. Journal of Clinical Oncology, 2013, 31, TPS2103-TPS2103.	1.6	0
188	QOL and neurocognitive functions in patients with GBM.. Journal of Clinical Oncology, 2014, 32, 2062-2062.	1.6	0
189	Ausgangslage f¼r Rehabilitationsmanahmen bei HirntumorpatientInnen. , 2020, , 227-236.		0
190	NIMG-13. RESPONSE ASSESSMENT IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL-BASED IMMUNOTHERAPY: A COMPARATIVE ANALYSIS OF MACDONALD, RANO, MRANO, IRANO AND VOLUMETRIC MEASUREMENTS. Neuro-Oncology, 2021, 23, vi130-vi130.	1.2	0